An observational study in Heart Failure, sponsored by Helse Nord-Trøndelag HF. Completed at 1 site in Norway. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-15.
Sponsored by Helse Nord-Trøndelag HF · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Heart Failure with a site in Norway — 16 open to participants now, 19 under way, 1 of them phase 3. Heart Failure · Norway.
Among the 104 studies in Heart Failure with a site in Norway, this one has the largest enrollment of the 21 observational ones that give a count, is one of 4 that started in 2017, is one of 21 observational ones, and was the 81st registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →16 of the 104 studies in Heart Failure with a site in Norway are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Norway, United States, Belgium and 7 more countries
Ages 18+
Rigshospitalet, Denmark · Sites in Norway, Denmark, Finland and 1 more country
Ages 18–99
Skane University Hospital · Sites in Norway, Sweden
Ages 18+
Bayer · Sites in Norway, Austria, Belgium and 14 more countries
Ages 18+
University Hospital of North Norway · Sites in Norway
Ages 40+ · Healthy volunteers
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36,511 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 270 across the 83 interventional studies, 200 across the 21 observational. Of the 75 that completed or were terminated, 28 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 104 have an industry lead sponsor. The 10 most frequent:
Helse Nord-Trøndelag HF is the lead sponsor of 27 studies on the registry; 5 are open to participants now.
Helse Nord-Trøndelag HF has 8 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
1 of the studies in Heart Failure with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07850726Norwegian University of Science and TechnologyDeep Learning-Based Automated Pressure-Strain Loop Analysis | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 104 studies in Heart Failure with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this population study aim is to evaluate risk factors for heart failure and combine these into a new heart failure risk score.
Secondly, the heart failure risk score will be internally and externally validated, and compared with established heart failure risk scores. Additionally, the prevalence of heart failure as well as the distribution of the heart failure risk score in the general population will be evaluated.
Explore which clinical risk factors or patient characteristics in a general population that are associated with increased risk for heart failure events and combine these into a new population-based heart failure risk score ("The HUNT for heart failure risk score") for predicting heart failure risk
Validate the newly developed heart failure risk score internally in the HUNT2 database
Compare the predictive ability of the new heart failure risk score with established heart failure risk scores (the ABC Health HF risk score, the Framingham HF risk score) and an established Norwegian cardiovascular risk score (NORRISK 2)
Estimate the prevalence of likely ("undiagnosed") heart failure , i.e., patients at high risk of HF, in a general population by using both the established heart failure risk scores and the newly developed heart failure risk score, and compare the heart failure event rate between those at high risk of heart failure and those with established heart failure.
General population
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
General population participating in the third wave of the HUNT study
Other: Heart failure risk estimation
General population participating in the second wave of the HUNT study
Other: Heart failure risk estimation
Evaluation by heart failure risk score
Time to incident heart failure event
Time to first heart failure hospitalization or heart failure related visit at the out-patient clinic (events defined according to the ESC 2016 heart failure guidelines)
Time frame: 10 years
Time to death from any cause
Time to death from any cause
Time frame: 10 years
Time to first heart failure event or death from any cause
Time to first heart failure event (hospitalization or HF related visit at the out-patient clinic) or death from any cause
Time frame: 10 years
Validity of heart failure risk score
Evaluation of the validity of heart failure risk score
Time frame: 10 years
Prevalence of heart failure
Prevalence of heart failure in a general population
Time frame: 0 days
Distribution of heart failure risk score categories
Distribution of the heart failure risk score categories in a general population
Time frame: 0 days
Plan to share: Undecided — Will follow the institutional regulations
No publications or documents are linked to this record.
Ran from Oct 2017 to primary completion in Jun 2023, 68 months.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's 68 months is above that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helse Nord-Trøndelag HF